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Activation of the phosphatidylinositol 3-kinase (PI3K)/AKT signaling
pathway is a frequent occurrence in human cancers and a major
promoter of chemotherapeutic resistance. Inhibition of one down-
stream target in this pathway, mTORC1, has shown potential to
improve chemosensitivity. However, the mechanisms and genetic
modifications that confer sensitivity to mTORC1 inhibitors remain
unclear. Here, we demonstrate that loss of TSC2 in the E-mycmurine
lymphoma model leads to mTORC1 activation and accelerated onco-
genesis caused by a defective apoptotic program despite compro-
mised AKT phosphorylation. Tumors from Tsc2/E-Myc mice un-
derwent rapid apoptosis upon blockade of mTORC1 by rapamycin.
We identified myeloid cell leukemia sequence 1 (Mcl-1), a bcl-2 like
family member, as a translationally regulated genetic determinant of
mTORC1-dependent survival. Our results indicate that the extent by
which rapamycin can modulate expression of Mcl-1 is an important
feature of the rapamycin response.
rapamycin response  Tsc2 loss  apoptosis  lymphoma  Akt
An important consequence of phosphatidylinositol 3-kinase(PI3K)/AKT pathway activation is stimulation of mammalian
target of rapamycin (mTOR), which is associated with altered cell
growth, cell survival, and therapeutic response.AKT signaling leads
to disruption of the tuberous sclerosis complex [composed of two
gene products TSC1 (Harmartin) and TSC2 (Tuberin)] that in turn
no longer attenuates RHEB-GTPase activity and results in mTOR
activation. There are two structurally distinct mTOR signaling
complexes in mammalian cells: the mTOR complex 1 (mTORC1)
and mTORC2 (1). One well characterized function of mTORC1 is
to maintain protein synthesis in homeostasis with the cellular
environment. It achieves this through phosphorylation of at least
two direct targets, eukaryotic initiation factor (eIF) 4E-binding
proteins (4E-BPs) and ribosomal protein S6 kinases (S6Ks) (2).
4E-BPs bind to and prevent eIF4E from entering into eIF4F, a
heterotrimeric complex required for the cap-dependent ribosome
recruitment phase of translation initiation. S6K also regulates
translation initiation by controlling the activity of eIF4A, a DEAD
box RNA helicase, essential to eIF4F function (3).
Rapamycin (Rap), an mTOR inhibitor, is currently being inves-
tigated as a therapy against numerous cancers (4). It targets
primarily mTORC1, although in some cell types, long-term expo-
sure to Rap interferes with mTORC2 activity, presumably by
sequestering newly synthesized mTOR and reducing nascent
mTORC2 complex formation (5). Although many cancers show
elevated mTORC1 activity, treatment with Rap (or its analogs) is
only effective against a subset of tumors (4). Identifying determi-
nants of Rap sensitivity is therefore critical to understanding when
mTOR inhibition could be an effective cancer therapy. Two pro-
posedmediators of theRap response are: (i) the ability of rapamycin
to reactivate AKT signaling, normally suppressed by S6K1 (6), and
(ii) elevated levels of eIF4E (7, 8), although the targets directly
mediating sensitivity remain unknown.
In this work, we use a preclinical mouse model to investigate the
effect of mTORC1 activation (via TSC2 loss) on translation initi-
ation, oncogenesis, and tumor chemosensitivity. We find that
Tsc2/E-Myc mice developed aggressive drug-resistant lympho-
mas that depended on mTORC1 activity for survival. We demon-
strate that myeloid leukemia cell sequence 1 (Mcl-1), an important
antiapoptotic regulator required for the maintenance of mature
lymphocytes, is translationally regulated by mTORC1.
Results
Loss of TSC2 Accelerates MYC-Induced Lymphomagenesis. In the
E-mycmouse tumors model, activation of AKT signaling leads to
accelerated tumorigenesis and drug resistance (8). Loss of AKT
signaling inhibits cell proliferation and oncogenesis, an effect that
can be rescued by hyperactivation of mTORC1, suggesting that
AKT may mediate its oncogenic effects exclusively through
mTORC1 (9).We therefore sought to determine whether a genetic
lesion downstream of AKT, and capable of activating mTORC1,
could accelerate lymphomagenesis and drug resistance in vivo.
Because inactivation of TSC fulfills these requirements (10), we
crossed Tsc2/ mice to Eu-Myc transgenic mice. E-Myc mice
developed tumors with a mean onset time of 114 days (Fig. 1A) (8,
11). Tsc2/ mice did not develop any lymphoid hyperplasia over
the course of thiswork. In contrast,Tsc2/E-Mycmice developed
tumors at a significantly accelerated rate (Fig. 1A, mean onset time
is 47 days, P 0.001). We found that the majority (66%) of tumors
from Tsc2/E-Myc mice had lost the remaining wild-type Tsc2
allele (Fig. 1B), an event also confirmed by immunoblotting
(J.R.M., unpublished observations). Tumors from Tsc2/E-Myc
mice did not infiltrate the visceral organs as aggressively as Akt-
drivenE-Myc tumors (8). They did, however, show a propensity to
invade the subarachnoid space of the brain, often accumulating in
blood vessels of the cerebellum where they induced infarction
leading to overt motor control defects [supporting information (SI)
Fig. S1]. Thus, loss of TSC2 greatly accelerated the onset and
severity of myc-driven lymphomas.
mTORC1 signaling was activated in primary Tsc2/E-Myc
tumors that underwent loss of heterozygosity (LOH; referred to in
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this work as Tsc2LOHE-Myc), as judged by phosphorylation of
S6K1 and 4E-BP1 (Fig. 1C; lanes 7–9). 4E-BP1 and S6K1 phos-
phorylation were elevated in E-Myc/myr-Akt tumors although not
as extensively (lanes 4–6). Tumors lacking lesions in the AKT/
mTORC1 pathway showed little phosphorylation of rpS6, S6K1,
and 4E-BP1 (lanes 1–3). Taken together, the results indicate robust
mTORC1 activation in Tsc2LOHE-Myc tumors.
Forced activation of AKT in the context of the E-Myc mouse
model results in tumors that show little change in proliferation rates
but have suppressed apoptosis (8). Immunohistochemical (IHC)
analysis confirmed that both tumor genotypes showed similar levels
of proliferation as revealed by Ki67 staining; however, Tsc2LOHE-
Myc tumors had reduced apoptotic rates, similar to what was
observed in AKT-driven tumors (Fig. 1D andE). IHC also verified
that mTORC1 was active because there was elevated p-S6 staining
in Tsc2LOHE-Myc tumors compared with Tsc2/E-Myc tumors
(Fig. 1D). This is consistent with activated mTORC1 regulating
programmed cell death in the E-Myc mouse model (8). The
impact of Tsc2 loss on tumor behavior was reminiscent of AKT-
driven lymphomas because Tsc2LOHE-Myc tumors maintained
functional p53, whereas E-Myc commonly do not (12). p53 alleles
were intact and lacked any mutations as determined by sequencing
of all 11 p53 exons from a panel of 11Tsc2LOHE-Myc tumors (data
not shown). Tsc2LOHE-Myc tumors retained p53 protein expres-
sion and repressed ARF expression (Fig. S2A). Detection of exon
1 of Arf verified the presence of the Arf locus (Fig. S2B), and
Tsc2LOHE-Myc tumors responded appropriately to -irradiation
by up-regulating p53 and p21 expression (Fig. S2C). Knockdown of
p53 in Tsc2LOHE-Myc tumors blocked induction of p21, whereas
p53/E-Myc tumors failed to activate p21 (Fig. S2C). Thus,
Tsc2LOHE-Myc tumors retained a functional p53 pathway.
Tsc2LOHE-Myc Lymphomas Have Defective AKT Activation. Loss of
TSC2 in mouse embryonic fibroblasts (MEFs) impairs AKT acti-
vation by blocking PI3K-dependent recruitment to the membrane,
where it is fully activated by phosphorylation on S473 by mTORC2
(13, 14). We tested the inducibility of AKT in Tsc2LOHE-Myc
tumors by measuring S473 phosphorylation after treatment with
various PI3K stimulators (Fig. 2A). Insulin, LPS, and IgM were
incapable of eliciting AKT (S473) phosphorylation in Tsc2LOHE-
Myc tumors (lanes 1–4). In contrast, Tsc2/E-Myc tumors were
responsive to these stimuli (lanes 5–8).
Another important consequence of loss of TSC2 is an alteration
in the distribution of mTOR among its complexes, mTORC1 and
mTORC2 (15). Loss of mTORC2 has been shown to stimulate
mTORC1 signaling (16). We therefore measured the proportion
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Fig. 2. Activation of mTORC1 leads to defective AKT phosphorylation in
MYC-induced lymphomagenesis. (A) Tumors of the indicated genotype were
cultured ex vivo and stimulated with 100 nM insulin, 10 g/ml LPS, or 10 g/ml
IgM. Extracts were prepared and probed for AKT (total and p-S473) and ACTIN.
(B) The distribution of mTOR among mTORC1 and mTORC2 is altered in
Tsc2LOHE-myc tumors.Tsc2/E-mycandTsc2LOHE-myc tumors were analyzed
for total levels of mTOR, RICTOR, and RAPTOR. MTOR-containing complexes
were immunoprecipitated from E-myc tumors of the indicated genotypes, and
RICTOR and RAPTOR levels were assessed by Western blotting. (Top) Total levels
of mTOR, RICTOR, and RAPTOR in whole-cell extracts. (Bottom) Amounts of
RICTOR and RAPTOR coprecipitating (Co-IP) with mTOR. The quantitation of
mTORC2:mTORC1 ratios in three tumors of the indicated genotype is shown and
represents the average of three experiments SD. (C) Tsc2/E-myc and
Tsc2LOHE-myc tumors were analyzed for levels of RICTOR-associated mTOR. (D)
Amounts of RICTOR and RAPTOR associating with mTOR in E-myc, Tsc2LOH,
myr-Akt, andPten/E-myc tumors. (E)AKT(S473)phosphorylation isdecreased
in Tsc2LOHE-myc tumors. Extracts prepared from MSCV/myr-Akt-infected
Tsc2/E-myc or Tsc2LOHE-myc tumors were analyzed by Western blotting for
AKT (total andp-S473), S6 (total andp-S235/236), and tubulin. AKT and myr-AKT
are denoted by an arrow and arrowhead, respectively.
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Fig. 1. Tsc2LOHE-myc tumors display accelerated lymphomagenesis and
activated mTORC1 signaling. (A) Kaplan–Meier plot illustrating differences in
tumor latencies between Tsc2/E-myc (red, n  41) and Tsc2/E-myc
(blue, n  29) mice (P  0.001 as determined by log rank analysis). (B) PCR to
detect LOH at the Tsc2 locus in Tsc2/E-myc tumors (wt, wild-type allele; mt,
mutant allele). (C) Western blot analysis of E-myc tumors of the indicated
genotypes probed for activation of AKT-mTOR signaling (p-AKT, -tubulin,
and phosphorylated and total S6K1, S6, and 4E-BP1). (D) Representative
micrographs ofTsc2/E-mycandTsc2LOHE-myc tumor sections stained with
H&E, by TUNEL, and for Ki-67. (E) Loss of TSC2 blocks MYC-induced apoptosis
to the same extent as AKT activation. The percentage of cells staining positive
for TUNEL from Tsc2/E-myc (n 4), Tsc2LOHE-myc (n 3), or E-myc/myr-
Akt (n  3) tumors is shown. Tumor tissue sections from three independent
animals were analyzed, with three randomly selected fields (500 cells)
analyzed for TUNEL signal. Error bars represent the SD. *, P 0.001; **, P0.4
as determined by Student’s t test.
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of mTOR present in mTORC1 (associating with RAPTOR) or
mTORC2 (associating with RICTOR) in Tsc2LOHE-Myc and
Tsc2/E-Myc tumors (Fig. 2B). Anti-mTOR antibodies immu-
noprecipitated less RICTOR from Tsc2LOHE-Myc lymphomas
compared with Tsc2/E-Myc lymphomas (Fig. 2B; 2.5-fold
decrease). Similarly, anti-RICTORantibodies immunoprecipitated
less mTOR in Tsc2LOHE-Myc tumors (Fig. 2C). Tsc2/p53/
MEFs had similar changes in mTORC1 and mTORC2 levels
compared with Tsc2/p53/ MEFs (Fig. S3). We also analyzed
mTOR complexes in Pten/E-Myc and E-Myc/myr-Akt tumors
and did not find significant changes in mTORC2:mTORC1 ratios
compared with E-Myc tumors (Fig. 2D, compare lanes 3 and 5
with 1). Loss of mTORC2 complexes could explain why we noted
only weak phosphorylation of constitutively membrane recruited
myr-AKT in Tsc2LOHE-Myc tumors (Fig. 2E). Hence, despite loss
of AKT activation, Tsc2LOHE-Myc tumors develop rapidly with a
suppressed apoptotic program.
mTORC1 Mediates Cell Survival in Tsc2LOHE-Myc Lymphomas.
Tsc2LOHE-Myc derived tumors had significantly lower levels of
apoptosis (Fig. 1E), prompting us to assess their drug sensitivity.
C57BL/6 mice bearing transplanted primary Tsc2LOHE-Myc lym-
phomas were treated with either doxorubicin (Dxr), rapamycin
(Rap), or combination therapy (Dxr  Rap) and monitored for
tumor-free survival. Here, animals bearing Arf/E-myc lympho-
mas were used as controls because these lymphomas are also highly
aggressive but remain chemosensitive (8, 17). Mice bearing control
tumors underwent complete remission for 18 days after Dxr
treatment (data not shown) as reported in ref. 8. Mice bearing
Tsc2LOHE-Myc lymphomas showed little response to Dxr, with
tumors relapsing by 5 days after treatment (Fig. 3A; P  0.001
relative to control lymphomas). Mice bearing control lymphomas
did not respond to Rap (data not shown), whereas mice harboring
Tsc2LOHE-Myc lymphomas showed complete remission for 10
days afterRap therapy (Fig. 3A; medium dash, P 0.001 compared
with control lymphomas). Tsc2LOHE-Myc lymphomas were highly
sensitive to the combination of Rap and Dxr, similar to what has
been observed for E-Myc/myr-Akt- derived lymphomas (Fig. 3A;
P  0.001 compared with single agents). This enhanced sensitivity
was associated with increased apoptosis as assessed by PARP
cleavage (Fig. 3B). Tsc2LOHE-Myc tumors rapidly underwent
apoptosis after a single dose of Rap in vivo (Fig. 3B and Fig. S4 A
and B). Arf/E-myc or E-Myc tumors were both unresponsive
to five consecutive daily doses of Rap in vivo (data not shown).
These differences were recapitulated ex vivo (Fig. 3 C and D).
An in vitro competition assay revealed that shRNAs directed
against RAPTOR were selected against whether Rap was present
or not, whereas decreasing RICTOR had no influence on Rap
sensitivity (Fig. 3E). shRNA directed against eIF4E, a downstream
effector of mTORC1, proved to be moderately selected against
under normal growth conditions; however, in the presence of Rap,
eIF4E shRNA-expressing tumors were eliminated from the popu-
lation. Taken together, our results suggest that mTORC1 mediates
survival signaling in Tsc2LOHE-Myc lymphomas.
Mcl-1 Translation Is mTORC1-Regulated. Activation of mTORC1 is
predicted to stimulate protein synthesis (2). Indeed,E-Myc tumors
lacking TSC2 showed a 2-fold increase in protein synthetic rates
compared with Tsc2/E-Myc tumors (Fig. 4A). This increased
translation is mTORC1-dependent because Rap inhibited transla-
tion to levels comparable with those observed in Tsc2/E-Myc
tumors (Fig. 4A). Similar results were obtained with Tsc2/p53/
and Tsc2/p53/ MEFs (Fig. S5A). To determine whether the
Rap-mediated decreases in translation were associated with altered
levels of eIF4F complex, we measured the relative levels of eIF4E-
binding partners, eIF4GI and 4E-BP1, associating with cap-bound
eIF4E (Fig. 4B). As expected, the amount of eIF4Gassociatingwith
eIF4E was reduced, whereas the amount of inhibitory 4E-BP1
increased in Rap-treated samples (compare lane 4 with 3). Thus,
Rap reduces eIF4F complexes in Tsc2LOHE-Myc tumors, and this
correlates with a decrease in translation rates.
Given that mTORC1 inhibition in Tsc2LOHE-Myc lymphomas
leads to a rapid onset of apoptosis, we postulated that activated
mTORC1 was promoting drug resistance by increasing the trans-
lation of antiapoptotic proteins. Unlike other antiapoptotic bcl-2-
like family members, MCL-1 is a highly unstable protein and
requires active translation to maintain its expression levels (18).
MCL-1 is necessary for early embryonic development and for
maintenance of hematopoietic cell lineages (19). In the E-Myc
mousemodel, eIF4Ehas been shown to regulateMCL-1 expression
(20). Indeed, we observed modest but consistent increases
Fig. 3. Rapamycin and doxorubicin cooperatively induce apoptosis in
Tsc2LOHE-myc tumors. (A) Kaplan–Meier plot detailing the time to relapse after
treatmentofmicebearingTsc2LOHE-Myc tumorswithDxr,Rap,oracombination
of both (DxrRap).P0.001 for significance among all curves as determined by
log rank test. (B) Extracts prepared fromTsc2LOHE-myc tumors treated withRap,
Dxr, or combination treatment were probed for cleaved PARP (cPARP), tubulin,
and rpS6 (S6 and p-S235/236). (C) Tsc2LOHE-myc tumors are more sensitive to
Rap-induced apoptosis than Tsc2/E-myc tumors. E-myc derived tumors
(Tsc2/ or Tsc2LOH) were cultured ex vivo in the presence of vehicle or 1 nM Rap
for 32 h. Propidium iodide and annexin V staining was used to quantify induction
of apoptosis. *, P  0.0007; **, P 0.2 as determined by Student’s t test. (D)
Tsc2LOHE-myc tumors are more sensitive to growth inhibition than Tsc2/E-
myc tumors. Cells were cultured ex vivo in the presence of the indicated concen-
trationsofRap for24handviabilitydeterminedbyusinganMTSassay(Promega).
Viability is standardizedtonontreatedcontrols (n3). (E)mTORC1,notmTORC2,
dictates sensitivity to Rap in Tsc2LOHE-myc lymphomas. (Upper) Tsc2LOHE-myc
lymphomas were cultured ex vivo and transduced with the indicated MLP-based
shRNA vectors. The percentage viable GFP cells was measured after a 60-h
exposure to 50 pM rapamycin or vehicle alone. The results are expressed relative
to percentage GFP cells present before rapamycin exposure (which was arbi-
trarily set at 1). Shown are averaged over three experiments, and error bars
represent theSEM. (Lower) Immunoblotsverifyingknockdownoftargetproteins
using the indicated MSCV-based shRNA retroviral vectors in NIH 3T3 cells.
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in MCL-1 expression in Tsc2LOHE-Myc tumors compared with
E-Myc tumors (Fig. 4C) and in Tsc2/p53/ MEFs compared
with Tsc2/p53/MEFs under low serum conditions (Fig. S5B).
Rescue of TSC2 expression in Tsc2/p53/ MEFs reduced
MCL-1 to levels observed in Tsc2/p53/ MEFs (Fig. S5B).
Inhibition of mTORC1 by Rap reduced MCL-1 to basal levels in
both Tsc2LOHE-Myc tumors and Tsc2/p53/ MEFs (Fig. 4C
and Fig. S5 B and C). Interestingly, in both lymphomas and MEFs
lacking a lesion activating mTORC1 signaling, Rap neither induced
apoptosis nor appreciably decreased MCL-1 expression (Fig. S5 B
and C). Hence, loss of MCL-1 expression by mTORC1 inhibition
occurs in the context of activated AKT/mTORC1 signaling.
To determine whether this was a consequence of a decrease in
Mcl-1 translation, we monitored the polysome distribution ofMcl-1
in untreated or Rap-treated Tsc2LOHE-Myc tumors (Fig. 4D). Rap
treatment of Tsc2LOHE-Myc tumors produced a depression in the
distribution of heavy polysomes and increased the amount of lighter
polysomes and free ribosomes (Fig. 4D). Quantitative RT-PCR
revealed a redistribution of Mcl-1 mRNA from heavy polysomes
(fraction 20–22) in Rap-treated cells toward lighter polysomes
(fraction 12–14). This contrasts with the behavior of -actinmRNA
from the same polysome fractions, which showed only slight dif-
ferences in distribution between untreated andRap-treated samples
(Fig. 4D).
Rapamycin-Induced Apoptosis Is Rescued by MCL-1 Overexpression.
These findings raised the question of whether Rap-induced apo-
ptosis in Tsc2LOHE-Myc tumors was initiated by the loss ofMcl-1
expression. To address this, we established an in vivo competition
assay that allowed us to generate genetically defined mixed tumor
populations and examine relative competitiveness of each popula-
tion in vivo (Fig. 5A). Tsc2LOHE-Myc tumors were freshly isolated
fromdonors and partially infectedwith eitherMSCV/gfp orMSCV/
Mcl-1/gfp. These populations were reintroduced into recipient
syngenic animals, and upon tumormanifestation, themice received
either vehicle orRap. Before therapy,micewere visualized to detect
GFP tumors in the abdominal region. At 12 h after Rap, the time
required to detect appreciable loss of tumor mass in Tsc2LOHE-
Myc mice, the same mice were again visualized to quantitate the
amount of GFP tumor cells (Fig. 5B). Rap treatment led to a
detectable decrease in the tumor size and correlated with a loss of
GFP signal intensity (Fig. 5B Left pair). In contrast, an increase in
GFP intensity was observed in mice bearing Tsc2LOHE-Myc
tumors infected with MSCV/Mcl-1/gfp (Fig. 5B Right pair). The
amount of GFP cells was quantitated by harvesting the residual
tumor cells and subjecting these to flow cytometry (Fig. 5C).
Enrichment of GFP cells after Rap therapy is clearly seen in
MSCV/Mcl-1/gfp-infected cells and indicates resistance to therapy.
Thus, Mcl-1 is a genetic modifier of Rap sensitivity.
Discussion
Here, we established that mTORC1 acts as a key mediator of AKT
prosurvival functions in B cell lymphomas driven by MYC over-
expression. Tsc2/E-Mycmice rapidly developed aggressive lym-
phomas with tumors frequently undergoing LOH (Fig. 1 A and B),
an event associated with hyperactive mTORC1 signaling (Fig. 1C).
The c-myc oncogene promotes apoptosis, such that genetic alter-
ations that disable apoptotic programs often accelerate MYC-
driven tumorigenesis (21). Not surprisingly, Tsc2LOHE-Myc lym-
phomas arose with defective apoptotic responses to oncogene
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Fig. 4. Rapamycin decreases expression of MCL-1 in
Tsc2LOHE-myc tumors. (A) E-myc-derived tumors (Tsc2/
orTsc2LOH) were culturedex vivo in the presence of vehicle or
10 nM Rap for 2 h followed by [35S]Met labeling for the
indicated times. Error bars represent SD (n  2). (B) Rap
treatment of Tsc2LOHE-myc tumors impairs recruitment of
eIF4GI into the eIF4F complex. Extracts from Tsc2LOHE-myc
and Tsc2/E-myc tumors were applied to m7GDP affinity
resins and washed, and m7GTP eluents were probed for
eIF4GI, eIF4E, and 4E-BP1. (C) Expression of Mcl-1 is mTOR-
dependent inTsc2LOHE-myccells.After1hofRap treatment,
MCL-1 levelsweredeterminedbyWesternblotting. (D)Trans-
lation of Mcl-1 is inhibited by Rap. Polysome profiles from
Tsc2LOHE-myc tumors grown ex vivo and exposed to 10 nM
Rap for 2 h are shown. RNA was isolated from polysome
fractions and subjected to quantitative RT-PCR analysis. The
relative amount of Mcl-1 or -actin mRNA in each fraction is
expressed as a percentage of the total in the polysome gra-
dient. Quantitative RT-PCRs were performed in duplicate,
and the error bars represent the SEM. Shown is one of three
representative experiments performed on different poly-
some gradients.
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activation and chemotherapy. These defects were reversible upon
mTORC1 inhibition. We reported that tumors in Pten/E-Myc
mice arise at a rate comparable to E-Myc mice. Interestingly,
Pten/E-Myc did not undergo LOH, nor did they arise with
robust activation of mTORC1 as seen in E-Myc/myr-Akt lympho-
mas or Tsc2LOHE-Myc lymphomas (8). These findings highlight
the importance of mTORC1 activity as a potent antiapoptotic
signal and as a critical arm of AKT-driven tumorigenesis in lym-
phoma development.
One mechanism by which mTORC1 activity can promote cell
survival is through increased availability of eIF4E for assembly into
the eIF4F, a rate-limiting complex required for the ribosome
recruitment phase of translation initiation (2, 22). Increased eIF4E
levels can effectively suppress c-myc-induced apoptosis in vivo and
alter chemosensitivity in vivo (8). We hypothesized that a sizeable
proportion of AKT survival signaling may result from deregulated
translation, perhaps through altering the recruitment of antiapo-
ptotic mRNAs to the translation apparatus (7, 8, 20). We find that
Tsc2LOHE-Myc lymphomas have 2-fold higher translation rates
than Tsc2/E-Myc lymphomas (Fig. 4A). mTORC1 inhibition
reduced translation rates to levels that resembled those observed in
Tsc2/E-Myc cells and decreased eIF4F levels (Fig. 4 A and B).
In contrast, translation rates in E-Myc tumors were minimally
affected byRap, consistent with the absence ofmTORC1 activation
in these tumors (Fig. 4A). By using an in vitro competition assaywith
shRNAs targeting components of mTOR signaling complexes, we
determined that the sensitivity to rapamycin was indeed mediated
through the mTORC1/eIF4E arm (Fig. 3E and data not shown).
Higher eIF4E levels preferentially increase the translation of
mRNAs having lengthy, GC-rich, highly structured 5UTRs and
drive cellular transformation and metastatic progression in preclin-
ical models (22). In this fashion, the translation of ‘‘weak’’ mRNAs
is preferentially affected when eIF4F levels are modulated by
mTORC1 (22, 23). Hence, treatment of Tsc2LOHE-Myc tumor
cells with rapamycin may reflect translation inhibition of weak
mRNAs (Fig. 4A).
One such mRNA is Mcl-1, which has a GC-rich (70%) 5
UTR (see NM021960). MCL-1 is a short-lived protein with a
complex mode of regulation. Our previous studies and work by
others have implicated MCL-1 as a potential downstream target of
eIF4E (20, 24, 25). Elimination of MCL-1 is required for the
initiation of apoptosis after UV irradiation. During DNA damage,
Mcl-1 protein synthesis is blocked, and the existing pool of MCL-1
is rapidly degraded by the proteasome (18). Inhibition of Mcl-1
expression is effective at inducing apoptosis in some human cancers
(26, 27). We demonstrate that Rap caused a decrease in MCL-1
levels in Tsc2LOHE-Myc tumors. This response is associated with
a decrease in the translational efficiency of theMcl-1 mRNA (Fig.
4 C and D) and induction of apoptosis (Fig. 3 B and D and Fig. S4
A andB). Consistent with deregulatedMcl-1 expressionmodulating
Fig. 5. Mcl-1 is a genetic modifier of rapamycin sensitivity
in vivo. (A) Schematic representation of the in vivo compe-
tition experimental design. (B) Freshly isolated Tsc2LOHE-
myc tumors were transduced ex vivo with MSCV/gfp or
MSCV/Mcl-1/gfp virus and introduced into syngenic mice.
Upon tumor formation, the GFP content of tumors was
determinedbyfluorescencewhole-bodyscanningwiththe
GE eXplore Optix. The fluorescence signal in each animal
was analyzed before and 12 h after a single dose of Rap.
The intensity of the GFP signal is depicted by color accord-
ing the bar scale at the right. (C) Representative flow cy-
tometry analysis of GFP expression in Tsc2LOHE-myc tu-
mors expressing gfp and Mcl-1 in the viable portion of
tumors harvested 12 h after Rap exposure.
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drug sensitivity, constitutive expression ofMcl-1 inTsc2LOHE-Myc
cells prevented tumor regression uponmTORC1 inhibition (Fig. 5).
Our results do not exclude the possibility that additional levels of
Mcl-1 regulation contribute to the effects reported herein, but they
do indicate thatMcl-1mRNA translation is an important target of
rapamycin in vivo. Tumors arisingwith activating lesions in theAKT
pathway often displayRap sensitivity. Interestingly, we find thatRap
only inhibitsMcl-1 expression in the context of activating lesions in
the AKT/mTORC1 pathway (Fig. S4C). In lymphomas, lacking
activation of this pathway, Rap does not induce tumor regression,
nor does it reduce expression of Mcl-1. Our findings highlight the
importance of mTORC1 activity as a potent antiapoptotic signal
through Mcl-1 and as a critical arm of PI3K/AKT-driven tumori-
genesis in lymphoma development.
Materials and Methods
Immunblotting. For immunoblots, 50 g of protein extract was typically loaded
per lane and electrophoretically separated on SDS/polyacrylamide gels. Proteins
were transferred to Immobilon-P membranes (Millipore). Specific proteins were
detected with antibodies listed in the SI Materials and Methods.
In Vivo TumorMonitoring. Tumors were analyzed for gfp expression by using the
GE eXplore Optix system (GE Healthcare) with a 470-nm emitting laser. Photon
emission counts were collected and converted to GFP signal intensity. Mice
bearing tumors were analyzed before and 12 h after Rap therapy.
Tumor Analyses. For generating whole-cell protein extracts, tumors were har-
vested, and single cell suspensions were made. These cells were treated with ACK
buffer [0.15 M NH4Cl, 0.1 mM EDTA, 0.01 M KHCO3 (pH 7.3)] to remove red blood
cells. Cells were pelleted, washed several times with ice-cold PBS, and resus-
pended in ice-cold lysis buffer [10 mM TrisHCl (pH 7.6), 1% Nonidet P-40, 0.5%
sodium desoxycholate, 0.1% SDS, 20 mM -glycerophosphate, 10 mM NaF, 100
mM NaCl, 1 mM EDTA, 1 mM EGTA, 1 g/ml pepstatin, 1 g/ml leupeptin, and 1
g/ml aprotinin] and left on ice for 15 min. The resulting lysates were then
sonicated on ice for 10 s, and debris was pelleted by centrifugation at 14,000	g
for 15 min at 4°C. The resulting supernatant was quantitated for protein con-
centration and frozen at80°C.
Coimmunoprecipitations. mTOR and RICTOR coimmunprecipitations were per-
formed according to published methods (28) with slight modifications, described
in SI Materials and Methods.
Polysome Analysis and Real-Time Quantitative RT-PCR. For polysome profiling,
Tsc2LOHE-myc lymphomasweretreatedfor2hwithvehicle (MeOH)or4.0mg/kg
Rap. Cells were then processed for polysome analysis as described in SI Materials
and Methods.
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